Skip to Content

Plus Therapeutics Inc PSTV

Morningstar Rating
$1.76 −0.07 (4.03%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

PSTV is trading at a 884% premium.
Price
$1.90
Fair Value
$2.34
Uncertainty
Extreme
1-Star Price
$38.54
5-Star Price
$5.58
Economic Moat
Khnpg
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if PSTV is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$1.83
Day Range
$1.721.95
52-Week Range
$0.993.22
Bid/Ask
$1.70 / $2.92
Market Cap
$10.04 Mil
Volume/Avg
189,995 / 80,300

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
20

Valuation

Metric
PSTV
Price/Earnings (Normalized)
Price/Book Value
Price/Sales
Price/Cash Flow
Price/Earnings
PSTV

Financial Strength

Metric
PSTV
Quick Ratio
0.31
Current Ratio
0.41
Interest Coverage
−40.33
Quick Ratio
PSTV

Profitability

Metric
PSTV
Return on Assets (Normalized)
−93.12%
Return on Equity (Normalized)
−3,154.08%
Return on Invested Capital (Normalized)
−230.25%
Return on Assets
PSTV
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Novo Nordisk A/S ADR
NVO
XpbwqztzNxmw$631.0 Bil
Vertex Pharmaceuticals Inc
VRTX
KjmgpfkxNfmcvjk$126.2 Bil
Regeneron Pharmaceuticals Inc
REGN
RhlcvncGrfjmxg$120.7 Bil
Moderna Inc
MRNA
PpqdkxgrcMmck$48.0 Bil
Alnylam Pharmaceuticals Inc
ALNY
CdsjzkqlYpzyv$31.6 Bil
argenx SE ADR
ARGX
HyxhyqmmRvmb$27.9 Bil
BioNTech SE ADR
BNTX
YzkhnfykPppl$20.9 Bil
Biomarin Pharmaceutical Inc
BMRN
GtnltbvmQxlykq$16.3 Bil
United Therapeutics Corp
UTHR
WbmtcmymHsqj$14.6 Bil
Incyte Corp
INCY
FxfdglzTvsqb$12.6 Bil

Sponsor Center